Premium
No evidence of benefit from citalopram in treatment of bipolar depression
Publication year - 2021
Publication title -
the brown university psychopharmacology update
Language(s) - English
Resource type - Journals
eISSN - 1556-7532
pISSN - 1068-5308
DOI - 10.1002/pu.30714
Subject(s) - citalopram , depression (economics) , serotonin reuptake inhibitor , medicine , placebo , bipolar disorder , psychiatry , clinical trial , anxiety , antidepressant , mood , alternative medicine , economics , macroeconomics , pathology
Patients receiving citalopram as adjunctive treatment for bipolar depression experienced no significant improvement relative to placebo in a clinical trial that measured both acute and maintenance treatment response. This was the first study to evaluate the efficacy of a serotonin reuptake inhibitor (SRI) for the maintenance treatment of bipolar depression. Results were published online Jan. 12 in the Journal of Clinical Psychiatry .